Document is current

Documents that mention this clinical trial

Waiting for JAK inhibitor safety data
https://doi.org/10.1136/rmdopen-2022-002236

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
https://doi.org/10.1136/annrheumdis-2019-216761

Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance
https://doi.org/10.1007/s40744-024-00693-y

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
https://doi.org/10.1136/annrheumdis-2019-216655

RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?
https://doi.org/10.1136/rmdopen-2021-001565

POS0519 RELATIONSHIP BETWEEN DISEASE ACTIVITY AND MAJOR ADVERSE EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS ON TOFACITINIB OR TNF INHIBITORS: A POST HOC ANALYSIS OF ORAL SURVEILLANCE
https://doi.org/10.1136/annrheumdis-2022-eular.1238

POS0239 RISK OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS AGED ≥50 YEARS WITH ≥1 CARDIOVASCULAR RISK FACTOR: RESULTS FROM A PHASE 3b/4 RANDOMISED STUDY OF TOFACITINIB VS TUMOUR NECROSIS FACTOR INHIBITORS
https://doi.org/10.1136/annrheumdis-2022-eular.1016

POS0674 RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS AGED ≥50 YEARS WITH RHEUMATOID ARTHRITIS AND ≥1 ADDITIONAL CARDIOVASCULAR RISK FACTOR: A POST HOC ANALYSIS OF ORAL SURVEILLANCE
https://doi.org/10.1136/annrheumdis-2022-eular.1234

Correspondence on ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update‘
https://doi.org/10.1136/annrheumdis-2020-218573

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
https://doi.org/10.1136/annrheumdis-2021-221276

POS0824 CARDIOVASCULAR (CV) AND MALIGNANCY EVENTS IN THE FILGOTINIB (FIL) RHEUMATOID ARTHRITIS (RA) CLINICAL DEVELOPMENT PROGRAM UP TO 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1425

Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406

POS0520 ASSOCIATION BETWEEN BASELINE STATIN TREATMENT AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF ORAL SURVEILLANCE
https://doi.org/10.1136/annrheumdis-2022-eular.1255

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance ^(Results)
https://doi.org/10.1136/ard-2022-222259

SAT0139 AGE-BASED (<65 VS ≥65 YEARS) INCIDENCE OF INFECTIONS AND SERIOUS INFECTIONS IN TOFACITINIB-, ADALIMUMAB- AND PLACEBO-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF PHASE 2, PHASE 3 AND PHASE 3B/4 TOFACITINIB STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.1432

Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study
https://doi.org/10.1136/rmdopen-2023-003912

OP0269 BIOMARKERS TO PREDICT RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB OR TUMOUR NECROSIS FACTOR INHIBITORS
https://doi.org/10.1136/annrheumdis-2022-eular.787

Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure
https://doi.org/10.1136/rmdopen-2021-001595

Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222405

Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry
https://doi.org/10.1136/annrheumdis-2020-218992

AB0530 A PRACTICAL FRAMEWORK FOR INDIVIDUALIZED BENEFIT/RISK ASSESSMENT AND CLINICAL DECISION-MAKING ON TREATMENT WITH TOFACITINIB
https://doi.org/10.1136/annrheumdis-2024-eular.2850

Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials
https://doi.org/10.1136/bmjopen-2023-082366

Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715

POS0827 CLINICAL OUTCOMES OF PATIENTS WITH RHEUMATOID ARTHRITIS WHO DISCONTINUED TOFACITINIB OR TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM ORAL SURVEILLANCE
https://doi.org/10.1136/annrheumdis-2023-eular.2670

OP0043 IMPACT OF CARDIOVASCULAR COMORBIDITIES ON EFFICACY OF TOFACITINIB VS TNFI IN RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.2688

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors
https://doi.org/10.1136/rmdopen-2022-002571

Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543

Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study
https://doi.org/10.1136/annrheumdis-2021-221915

Documents that mention this clinical trial

Waiting for JAK inhibitor safety data
https://doi.org/10.1136/rmdopen-2022-002236

Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
https://doi.org/10.1136/ard-2023-223850

Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA
https://doi.org/10.1136/bmjopen-2023-072300

JAK inhibitors for inflammatory bowel disease: recent advances
https://doi.org/10.1136/flgastro-2023-102400

Documents that mention this clinical trial

Waiting for JAK inhibitor safety data
https://doi.org/10.1136/rmdopen-2022-002236

Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy
https://doi.org/10.1136/rmdopen-2025-005521

Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
https://doi.org/10.1007/s40744-023-00621-6

POS0639 BENEFIT–RISK ANALYSIS OF UPADACITINIB VERSUS ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND HIGHER OR LOWER RISK OF CARDIOVASCULAR DISEASE
https://doi.org/10.1136/annrheumdis-2024-eular.1416

OP0225 EVALUATION OF RESPONSE TO ADJUVANTED RECOMBINANT ZOSTER VACCINATION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB: RESULTS FROM A RANDOMIZED TRIAL SUB-STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.2386

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
https://doi.org/10.1136/rmdopen-2022-002735

Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE
https://doi.org/10.1007/s40744-024-00658-1

Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease
https://doi.org/10.1136/rmdopen-2024-005371

Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study
https://doi.org/10.1136/rmdopen-2023-004007

MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2023-003392

FRI0089 COMPARATIVE EFFICACY (ACR 20) OF TOCILIZUMAB TO OTHER TARGETED IMMUNE MODULATORS (TIM) FOR RHEUMATOID ARTHRITIS: A NETWORK META-ANALYSIS (NMA)
https://doi.org/10.1136/annrheumdis-2020-eular.532

Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2020-218412

OP0020 IMMUNOGENICITY OF AN ADJUVANT RECOMBINANT ZOSTER VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH UPADACITINIB: 60-WEEK RESULTS FROM A RANDOMIZED SUBSTUDY
https://doi.org/10.1136/annrheumdis-2024-eular.763

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
https://doi.org/10.1136/annrheumdis-2019-215764

FRI0137 UPADACITINIB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: RESULTS FROM SELECT-COMPARE
https://doi.org/10.1136/annrheumdis-2019-eular.287

POS0643 ASSOCIATION OF EARLY REMISSION ON CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS: POST-HOC ANALYSIS OF DATA FROM THE SELECT-COMPARE STUDY
https://doi.org/10.1136/annrheumdis-2024-eular.1469

Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2023-223916

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme ^{(Post-results)}
https://doi.org/10.1136/annrheumdis-2020-218510

POS0894 SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
https://doi.org/10.1136/annrheumdis-2024-eular.809